Articles tagged with: Vorinostat

News»

[ by | Sep 26, 2012 11:37 am | Comments Off ]
New Agents In Combination With Revlimid Show Promise For Relapsed / Refractory Multiple Myeloma

Treatment strategies that combine Revlimid with newer types of anti-tumor agents may be effective for relapsed and refractory multiple myeloma, according to myeloma experts who reviewed results from studies of these new combinations.

Refractory and relapsed multiple myeloma is notoriously difficult to treat. For every remission period that is achieved, relapse typically arises sooner and with greater resistance to previously used therapies. These patients have limited options for therapy.

In examining trials that tested new therapies in combination with Revlimid (lenalidomide), the authors of the review hoped to find …

Read the full story »

News»

[ by | Aug 21, 2012 10:40 am | 2 Comments ]
Revlimid Maintenance Therapy Gets NCCN Vote Of Confidence

The National Comprehensive Cancer Network (NCCN) has updated its guide­lines for the treatment of multiple myeloma, and the new guidelines will be interpreted by many as a vote of confidence for Revlimid maintenance therapy.

The NCCN guidelines are followed closely by physicians and by many U.S. health insurance companies, which frequently use them when making reim­burse­ment decisions about different cancer treatments.

The guidelines are comprised of recommendations based on the results of recent clinical trials and ongoing scientific research.  A panel of specialists within the myeloma field is responsible for …

Read the full story »

News»

[ by and | Jan 4, 2012 2:20 pm | 2 Comments ]
Zolinza Tallies Mixed Results In Relapsed And Refractory Multiple Myeloma Patients (ASH 2011)

Four clinical trials presented at the American Society of Hematology (ASH) 2011 annual meeting in San Diego last month suggest that Zolinza, in combination with a number of approved myeloma drugs, may be a treatment option for relapsed and treatment-resistant multiple myeloma patients.

However, results of a key Phase 3 trial involving the drug were disappointing, and they call into question whether the drug will receive formal FDA approval as a treatment for myeloma.

Zolinza (vorinostat), which is marketed by the U.S. pharmaceutical company Merck (NYSE: MRK), is an oral …

Read the full story »

News»

[ by | Dec 23, 2011 7:09 pm | One Comment ]
ASH 2011 – Initial Thoughts On The Meeting’s Key Myeloma-Related Findings

It has been ten days since the 2011 annual meeting of the American Society of Hematology (ASH) came to a close.

Since the meeting started, The Beacon has been providing detailed coverage in the form of discussion forum postings, daily updates, and in-depth articles about key research findings.

In this and The Beacon’s next article about the meeting, however, the per­spective changes a bit.

The focus shifts to the bigger picture — to questions like: “What was the impact of the …

Read the full story »

News»

[ by | Dec 20, 2011 4:04 pm | Comments Off ]
ASH 2011 Multiple Myeloma Update – Day Three Afternoon: Other New Therapies

As the third day of the 2011 American Society of Hematology (ASH) annual meeting came to an end, attendees could look back on an agenda that featured presentations about a wide range of potential new myeloma therapies.

The afternoon myeloma sessions were focused, in fact, on potential new therapies.

The Beacon’s previous ASH 2011 update covered the afternoon presentations about carfilzomib and pomalidomide, two potential myeloma therapies that are in the late stages of development.

This update covers the afternoon’s presentations about four other potential new myeloma therapies — …

Read the full story »